Rhone-Poulenc Rorer Azmacort
Lung deposition data for inhaled products must be correlated with clinical effects before they can be used in promotional materials, FDA tells RPR July 9. A company claim that Azmacort (triamcinolone) "delivers the right dose to the right place every time" implies clinical benefit without any supportive data, FDA says. Referring to a Feb. 26 discussion with the company, FDA reminds RPR that clinical pharmacology PET imaging, as used in the ad to illustrate lung deposition, is "not a validated surrogate measure of clinical effect." The agency also found that the phrases "right dose" and "right place" imply superiority over other orally-inhaled products: "i.e., any other dose to any other place is wrong or inappropriate," the letter concludes
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth